Press Releases
Bioneer and Qatar Petroleum singed $4 million Agreement on supply of COVID-19 diagnosis kit and inst
관리자 / 2022-09-01
Bioneer (CEO Han-oh Park) specializing in
molecular diagnostics announced that it has signed an agreement with Qatar
Petroleum, a state-owned company, to supply $4 million worth molecular
diagnostic instruments and coronavirus detection kits in Qatar.
Under the agreement, Bioneer will supply
Qatar Petroleum with COVID-19 molecular diagnostic kits, nucleic acid
extraction reagents and 18 molecular diagnostic instruments such as ExiPrep™
96 Lite and Exicycler™. Supplied instruments and kits for COVID-19
molecular diagnosis will be applied in medical institutions including the
Medical Services Department of Qatar Petroleum.
Bioneer provides a total solution for
molecular diagnosis with its gene extraction instrument, real-time PCR
instrument, extraction reagents and assays for amplifying and analyzing genes
required for COVID-19 detection and diagnostics. All Bioneer’s instruments,
reagents and kits are developed by the proprietary technologies in-house.
Bioneer supplies COVID-19 related
diagnostic instruments and kits to various countries around the world,
including a recent $1.9 million agreement to supply its molecular diagnostic
system ExiStation™ and COVID-19 detection kits in Romania.
Bioneer said that “Bioneer’s molecular
diagnostic system ExiStation™ is based on Real-Time PCR and RNA
extraction equipment. It is equipped with an automated system and can be
operated after a short-term training.”
The company added that in addition to
COVID-19, Bioneer's molecular diagnostic instrument is capable of testing
various infectious diseases, such as HIV, Hepatitis B, Hepatitis C, Sexually
Transmitted Infections and Tuberculosis using a molecular diagnostic kit
developed by the company.
About the ExiStation™ system
The ExiStation™ was developed
and launched by BIONEER, and it is the automatic molecular diagnostic system
composed with nucleic acid extractor, ExiPrep™, and real-time
PCR, Exicycler™.
Bioneer is the first and only company in
Asia to receive CE-IVD, List A certification for HIV-1, HBV, and HCV assays
with ExiStation™, which was based on the results of comparative
clinical trials with Roche’s COBAS 8800 system.
The ExiStation™ is an automated
molecular diagnostic system, which can reduce the error of the inspector and
derive quick and accurate test results. The system can be expanded and
configured according to the size of the laboratory, the number of specimens,
and the type of tests.
About the COVID-19 test kit
Bioneer received CE-mark certification for
‘AccuPower® COVID-19 Real-Time RT-PCR Kit’ and ‘AccuPower® SARS-CoV-2
Real-Time RT-PCR Kit’.
It leverages the company’s original
patented technology Dual-HotStart™. It can detect RNA targets from
clinical samples with high sensitivity and specificity through eliminating
non-specific synthesis and amplification.
About BIONEER Corporation
Established in 1992, BIONEER is the first
Korean biotechnology company with aim of the complete localization of genetic
technology and is publicly traded at KOSDAQ since 2005.
BIONEER’s multiplex molecular diagnostics
kit for the ZIKA, dengue and chikungunya viruses was listed in Emergency Use
Assessment and Listing (EUAL) from WHO in 2016.
In 2018, BIONEER received its first CE-IVD,
List A mark for HIV diagnosis kit and afterward, it was registered on the
purchase list of international non-profit financing organization, Global Fund.
In 2019, BIONEER received its second
CE-IVD, List A mark for HCV diagnosis kit.
In 2020, BIONEER received its third CE-IVD,
List A mark for HBV diagnosis kit and its HCV diagnosis kit was registered on
the purchase list of Global Fund.